Parabilis Sets Biotech IPO Record
June 15, 2026
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
1 min read
False
June 15, 2026
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
1 min read
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
By Joe Renny
June 5, 2026
The $787M financing points to a new global architecture in biotech
5 min read
June 3, 2026
Jonathan Maurer of the University of Geneva discusses his work with Sanofi and Waters – and why good analytical science has a lot in common with good cooking
3 min read
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
By James Strachan
June 1, 2026
Kelly Broster of Thermo Fisher Scientific explains why GLP-1 peptides are exposing the limits of traditional analytical workflows
12 min read
By Stephanie Harden, Tracy Hibbs
May 29, 2026
Accelerating analytical data management for the next-generation laboratory
7 min read
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
May 22, 2026
A new series championing analytical scientists in pharma begins with Genentech’s rising star
7 min read
By Manuel Möller
May 21, 2026
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
5 min read
False
False
False
Affiliations:
Specialties:
Areas of Expertise: